LUDIOMIL
LOE ApproachingNDAORALTABLET
Approved
Dec 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUDIOMIL is an oral tablet small-molecule antidepressant approved by Novartis in 1980. The specific mechanism of action and indications are not publicly detailed in available data. This is a legacy psychiatric medication in the mature/declining phase of its commercial lifecycle.
LOE Approaching
Product faces moderate competitive pressure (30/100) with limited growth opportunities as loss of exclusivity approaches, signaling smaller team focus and defensive positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product offers limited career upside with zero linked job openings and declining lifecycle stage. Positions on LUDIOMIL typically focus on managing a legacy asset through patent expiry and generic entry rather than driving growth or innovation.
Brand ManagerMedical Science Liaison
Worked on LUDIOMIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.